Incyte Announces FDA Approval of Jakafi XR (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
FDA DecisionapprovedJakafi XRPositive
AI Analysis
Summary
Incyte announced FDA approval of Jakafi XR (ruxolitinib) extended-release tablets for treating myelofibrosis, polycythemia vera, and graft-versus-host disease. This approval represents a significant expansion of the Jakafi franchise with a new formulation.
Outcome Details
FDA approved Jakafi XR (ruxolitinib) extended-release tablets for treatment of adults with myelofibrosis, polycythemia vera, and graft-versus-host disease
Importance:9/10
Sentiment:
0.95
FDA approvaloncologyhematologyextended-release formulationJAK inhibitor
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on May 1, 2026 2:05 AM